Inhibition of KIF20A by Transcription Factor IRF6 Affects the Progression of Renal Clear Cell Carcinoma

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2021 May 4

PMID 33941190

Citations 12

Authors

Xinwei Ma

Xiaoqi Wang

Qian Dong

Hongquan Pang

Jianming Xu

Junkang Shen

Jianbing Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Renal clear cell carcinoma (ccRCC) is one of the most common malignant tumors, whose incidence is increasing year by year. IRF6 plays an important role in the occurrence of tumors, although there is yet no report on its expression in ccRCC.

Methods: The expression of IRF6 and KIF20A in ccRCC was predicted by GEPIA and HAP databases. In addition, GEPIA database predicted the relationship between IRF6 and KIF20A expressions and the pathological staging, overall survival, and disease-free survival of ccRCC. The possible binding sites of IRF6 and KIF20A promoters were predicted by JASPAR database and verified by luciferase and ChIP assays. The specific effects of IRF6 on ccRCC cell proliferation, invasion and apoptosis were subsequently examined at both cellular level and animal level.

Results: The database predicted down-regulated IRF6 expression in renal carcinoma tissues and its correlation with poor prognosis. IRF6 overexpression inhibited cRCC cell proliferation, invasion and migration. In addition, up-regulated KIF20A expression in renal carcinoma tissues and its association with prognosis were also predicted. Interference with KIF20A inhibited the proliferation, invasion, and migration of ccRCC cells. Finally, we confirmed that KIF20A is a functional target of IRF6 and can partially reverse the effects of IRF6 on the proliferation, invasion and migration of ccRCC cells.

Conclusion: Inhibition of KIF20A by transcription factor IRF6 affects cell proliferation, invasion and migration in renal clear cell carcinoma.

Citing Articles

Plasma DNA Methylation-Based Biomarkers for MPNST Detection in Patients With Neurofibromatosis Type 1.

Tomczak K, Patel M, Bhalla A, Peterson C, Landers S, Callahan S Mol Carcinog. 2024; 64(1):44-56.

PMID: 39600120 PMC: 11636586. DOI: 10.1002/mc.23825.

The multiple roles of interferon regulatory factor family in health and disease.

Wang L, Zhu Y, Zhang N, Xian Y, Tang Y, Ye J Signal Transduct Target Ther. 2024; 9(1):282.

PMID: 39384770 PMC: 11486635. DOI: 10.1038/s41392-024-01980-4.

Development and validation of a combined hypoxia- and metabolism-related prognostic signature to predict clinical prognosis and immunotherapy responses in clear cell renal cell carcinoma.

Wu X, Xie W, Gong B, Fu B, Chen W, Zhou L Front Oncol. 2023; 13:1162846.

PMID: 38023248 PMC: 10667439. DOI: 10.3389/fonc.2023.1162846.

KIF20A as a potential biomarker of renal and bladder cancers based on bioinformatics and experimental verification.

Wang H, Ma X, Li S, Su J, Fan B, Liu B Aging (Albany NY). 2023; 15(11):4714-4733.

PMID: 37310408 PMC: 10292905. DOI: 10.18632/aging.204736.

Construction of an interferon regulatory factors-related risk model for predicting prognosis, immune microenvironment and immunotherapy in clear cell renal cell carcinoma.

Pan H, Lu W, Zhang M, Liu C Front Oncol. 2023; 13:1131191.

PMID: 37182129 PMC: 10174435. DOI: 10.3389/fonc.2023.1131191.

References

Zengin T, Ekinci B, Kucukkose C, Yalcin-Ozuysal O . IRF6 Is Involved in the Regulation of Cell Proliferation and Transformation in MCF10A Cells Downstream of Notch Signaling. PLoS One. 2015; 10(7):e0132757. PMC: 4498616. DOI: 10.1371/journal.pone.0132757. View

Oberbeck N, Pham V, Webster J, Reja R, Huang C, Zhang Y . The RIPK4-IRF6 signalling axis safeguards epidermal differentiation and barrier function. Nature. 2019; 574(7777):249-253. DOI: 10.1038/s41586-019-1615-3. View

Xu L, Huang T, Hu H, Wang M, Shi S, Yang Q . The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasopharyngeal carcinoma. Cancer Lett. 2017; 431:230-243. DOI: 10.1016/j.canlet.2017.10.016. View

Chen W, Hill H, Christie A, Kim M, Holloman E, Pavia-Jimenez A . Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016; 539(7627):112-117. PMC: 5340502. DOI: 10.1038/nature19796. View

Zhou Y, Yang L, Zhang X, Chen R, Chen X, Tang W . Identification of Potential Biomarkers in Glioblastoma through Bioinformatic Analysis and Evaluating Their Prognostic Value. Biomed Res Int. 2019; 2019:6581576. PMC: 6500689. DOI: 10.1155/2019/6581576. View

Ni M, Liu X, Wu J, Zhang D, Tian J, Wang T . Identification of Candidate Biomarkers Correlated With the Pathogenesis and Prognosis of Non-small Cell Lung Cancer via Integrated Bioinformatics Analysis. Front Genet. 2018; 9:469. PMC: 6194157. DOI: 10.3389/fgene.2018.00469. View

Rath O, Kozielski F . Kinesins and cancer. Nat Rev Cancer. 2012; 12(8):527-39. DOI: 10.1038/nrc3310. View

Degen M, Wiederkehr A, La Scala G, Carmann C, Schnyder I, Katsaros C . Keratinocytes Isolated From Individual Cleft Lip/Palate Patients Display Variations in Their Differentiation Potential . Front Physiol. 2018; 9:1703. PMC: 6281767. DOI: 10.3389/fphys.2018.01703. View

Akhtar M, Al-Bozom I, Al Hussain T . Molecular and Metabolic Basis of Clear Cell Carcinoma of the Kidney. Adv Anat Pathol. 2018; 25(3):189-196. DOI: 10.1097/PAP.0000000000000185. View

10.

Shen T, Yang L, Zhang Z, Yu J, Dai L, Gao M . KIF20A Affects the Prognosis of Bladder Cancer by Promoting the Proliferation and Metastasis of Bladder Cancer Cells. Dis Markers. 2019; 2019:4863182. PMC: 6481133. DOI: 10.1155/2019/4863182. View

11.

Slattery M, Lundgreen A, Bondurant K, Wolff R . Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011; 32(11):1660-7. PMC: 3204348. DOI: 10.1093/carcin/bgr189. View

12.

Taniguchi T, Ogasawara K, Takaoka A, Tanaka N . IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001; 19:623-55. DOI: 10.1146/annurev.immunol.19.1.623. View

13.

Restivo G, Nguyen B, Dziunycz P, Ristorcelli E, Ryan R, Yalcin Ozuysal O . IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J. 2011; 30(22):4571-85. PMC: 3243593. DOI: 10.1038/emboj.2011.325. View

14.

Zhang H, Zou J, Yin Y, Zhang B, Hu Y, Wang J . Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma. PeerJ. 2019; 7:e8096. PMC: 6883955. DOI: 10.7717/peerj.8096. View

15.

Turajlic S, Swanton C, Boshoff C . Kidney cancer: The next decade. J Exp Med. 2018; 215(10):2477-2479. PMC: 6170181. DOI: 10.1084/jem.20181617. View

16.

Li D, Cheng P, Wang J, Qiu X, Zhang X, Xu L . IRF6 Is Directly Regulated by ZEB1 and ELF3, and Predicts a Favorable Prognosis in Gastric Cancer. Front Oncol. 2019; 9:220. PMC: 6458252. DOI: 10.3389/fonc.2019.00220. View

17.

Yuan L, Chen L, Qian K, Qian G, Wu C, Wang X . Co-expression network analysis identified six hub genes in association with progression and prognosis in human clear cell renal cell carcinoma (ccRCC). Genom Data. 2017; 14:132-140. PMC: 5683669. DOI: 10.1016/j.gdata.2017.10.006. View

18.

Wei W, Lv Y, Gan Z, Zhang Y, Han X, Xu Z . Identification of key genes involved in the metastasis of clear cell renal cell carcinoma. Oncol Lett. 2019; 17(5):4321-4328. PMC: 6447949. DOI: 10.3892/ol.2019.10130. View

19.

Cheng S, Chuah K . Metastatic Renal Cell Carcinoma to the Pancreas: A Review. Arch Pathol Lab Med. 2016; 140(6):598-602. DOI: 10.5858/arpa.2015-0135-RS. View

20.

Zhu Z, Jin Z, Zhang H, Zhang M, Sun D . Knockdown of inhibits growth of tumors in soft tissue sarcoma and . J Cancer. 2020; 11(17):5088-5098. PMC: 7378921. DOI: 10.7150/jca.44777. View